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Abstract
Background: Depression and bipolar disorder are associated with reduced neural plasticity and deficits in memory,
attention and executive function. Drug treatments for these affective disorders have insufficient clinical effects in a
large group and fail to reverse cognitive deficits. There is thus a need for more effective treatments which aid
cognitive function. Erythropoietin (Epo) is involved in neuroplasticity and is a candidate for future treatment of
affective disorders. The investigators have demonstrated that a single dose of Epo improves cognitive function and
reduces neurocognitive processing of negative emotional information in healthy and depressed individuals similar
to effects seen with conventional antidepressants. The current study adds to the previous findings by investigating
whether repeated Epo administration has antidepressant effects in patients with treatment resistant depression and
reverses cognitive impairments in these patients and in patients with bipolar disorder in remission.
Methods/design: The trial has a double-blind, placebo-controlled, parallel-group design. 40 patients with
treatment-resistant major depression and 40 patients with bipolar disorder in remission are recruited and
randomised to receive weekly infusions of Epo (Eprex; 40,000 IU) or saline (NaCl 0.9%) for 8 weeks. Randomisation
is stratified for age and gender. The primary outcome parameters for the two studies are: depression severity
measured with the Hamilton Depression Rating Scale 17 items (HDRS-17) [1] in study 1 and, in study 2, verbal
memory measured with the Rey Auditory Verbal Learning Test (RAVLT) [2,3]. With inclusion of 40 patients in each
study we obtain 86% power to detect clinically relevant differences between intervention and placebo groups on
these primary outcomes.
Trial registration: The trial is approved by the Local Ethics Committee: H-C-2008-092, Danish Medicines Agency:
2612-4020, EudraCT: 2008-04857-14, Danish Data Agency: 2008-41-2711 and ClinicalTrials.gov: NCT 00916552.
Background and objective
Background
Depression and bipolar disorder are associated with
neurodegenerative processes, reduced neuroplasticity
and neuropsychological dysfunction, which often persist
even after clinical remission. Current pharmacological
treatment strategies have several limitations including a
significant treatment-onset-response delay, only partial
or no response in a large group of patients and limited
effects on their cognitive deficits, which often persist
into periods of remission [4-9]. These enduring cogni-
tive impairments affect patients’ psychosocial and occu-
pational function, quality of life and prognosis
[7,8,10,11]. Better treatment options are thus required to
improve the onset of efficacy, address patients who are
treatment resistant and remediate neurocognitive defi-
cits. Converging evidence suggests that neural atrophy
and reduced neuroplasticity are involved in depression
and bipolar disorder, while restoration of synaptic plasti-
city may be an important mechanism of chronic antide-
pressant and mood stabilising drug treatment [12-14].
This hypothesis is supported by evidence that increased
hippocampal brain-derived neurotrophic factor (BDNF)
is necessary for the behavioural effects of antidepressant
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pocampus mimics the behavioural effects of antidepres-
sants in rodents [16]. These effects and the role of
BDNF in learning and memory suggest that compounds,
which induce rapid and prolonged upregulation of neu-
roplasticity, may reduce the latency to antidepressant
effects and alleviate neurocognitive dysfunction.
Erythropoietin (Epo) has interesting properties, which
make it a candidate for investigation as a novel thera-
peutic agent in neuropsychiatric diseases. It is used for
the treatment of anaemia but has received renewed
attention because of its direct neurobiological actions
mediated through a non-haematopoietic Epo receptor
system in the brain [17]. Systemically administered Epo
crosses the blood-brain barrier (BBB) and has neuropro-
tective and neurotrophic effects in animal models of
acute brain damage and chronic neurodegenerative con-
ditions [18,19]. In humans, repeated Epo administration
improves neuropsychological function in patients with
schizophrenia [20] and multiple sclerosis [21]. Several
complex biochemical pathways mediate these actions,
including rapid up-regulation of neuroplasticity mechan-
isms including BDNF and neurogenesis [22,23], and
anti-inflammatory actions [24,25].
Functional magnetic resonance imaging (fMRI) evi-
dence highlights the functional neuroanatomy of emo-
tional processing and working memory as potential
neurobiological markers for depression [26,27]. Antide-
pressant drugs with different neurochemical actions
show similar effects in such human biomarker models
relevant to depression and antidepressant effects. In par-
ticular, serotonergic and noradrenergic antidepressants
increase the neural and cognitive processing of positive
emotional information and down-regulate the processing
of negative threat-relevant information after acute and 7
days administration and in the absence of changes in
mood in healthy volunteers [28,29] and in depressed
patients [30]. Such actions contrast with heightened
recognition and neural responses to threatening infor-
mation in depression [31,32] and may be an important
mechanism of antidepressant drug treatment. We have
recently reported cognitive and neural effects of a single
dose of Epo (40,000 IU; i.v.) in human models of antide-
pressant drug action independent of any haematological
effects in healthy volunteers [33-36]. In particular, Epo
enhanced memory-relevant hippocampal engagement
during picture retrieval 1 week post administration [34]
consistent with increased hippocampal BDNF and plasti-
city [37,38]. Epo also modulated fronto-parietal activa-
tion during spatial working memory (WM) and
improved verbal fluency performance at this time after
administration [35]. Finally, Epo reduced parietal-
occipital activation during presentation of fearful facial
expressions and the behavioural recognition of this
emotion [33] consistent with decreased attentional pro-
cessing and perception of threat-relevant stimuli 7 days
post administration similar to effects seen with conven-
tional antidepressant drug administration to healthy
volunteers [28,29]. Notably, we demonstrated a similar
reduction in the neural and cognitive response to nega-
tive threat-relevant picture stimuli following a single
dose of Epo vs. placebo to acutely depressed patients
[39]. Together with its known effects on neuroplasticity
in animal models, these findings highlight Epo as a new
candidate treatment for affective disorders.
Objective
The aim of the study is to investigate whether these
early effects of Epo translate into improvement of mood
and neurocognitive function with repeated administra-
tion in patients with treatment-resistant depression or
bipolar disorder in remission and to elucidate the
underlying biomarkers of potential treatment effects.
Beneficial effects on these measures would highlight Epo
as a candidate for adjunct treatment for affective disor-
ders to attenuate mood symptoms and aid cognitive
function in these patients groups.
Methods
Study design
The present trial has a double-blind, placebo-controlled,
parallel-group design in which participants are rando-
mised to receive weekly infusions of either Epo (Eprex;
40,000 IU; Janssen-Cilag) or saline over 8 weeks.
Patients complete a broad neurocognitive test battery
assessing memory, executive function and attention at
baseline, after completion of treatment (week 9) and at
follow-up (week 14). Mood, symptoms and quality of
life are measured at baseline and weeks 5, 9 and 14
using a variety of rating scales including the Hamilton
Depression Rating Scale 17 items (HDRS-17) [1], Young
Mania Rating Scale (YMRS) [40], Beck Depression
Inventory (BDI) [41], Massachusetts General Hospital
Cognitive and Physical Functioning Questionnaire
(CPFQ) [42], and the EuroQol visual analogue scale
(VAS) for quality of life (EQ-5D) [43]. Patients undergo
an fMRI scan at baseline and week 14. Further, plasma
and whole blood BDNF and inflammatory markers will
be investigated with blood tests at baseline and weeks 5,
9 and 14. Finally, we will assess metabolic parameters
with blood tests at baseline and weeks 5, 9 and 14, and
body fat mass by Dual energy X-ray absorptiometry
(DXA) scanning at baseline and week 9. For an overview
of investigations and their timing see table 1.
Participants and screening
Patients with treatment-resistant major depression
(study 1) and patients with bipolar disorder in full or
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will be recruited through Clinic for Affective Disorders,
Department of Psychiatry, Copenhagen University Hos-
pital, Rigshospitalet. The centre receives patients with
treatment-resistant major depression or bipolar disorder
from the whole Capital Region. Patients will be screened
with Schedules for Clinical Assessment in Neuropsy-
chiatry (SCAN) [44] to confirm diagnosis.
Inclusion Criteria are a diagnosis of either treatment-
resistant major depression (defined as failure to respond
to at least two different types of antidepressants given in
sufficient doses over sufficient time) in moderate to
severe degree (HDRS score ≥ 17), or bipolar disorder in
full or partial remission (HDRS ≤ 14 and YMRS ≤ 14)
and subjective experience of moderate to severe cogni-
tive problems on the CPFQ (score ≥ 4o n≥ 2 domains),
age between 18-65 years and unchanged antidepressant
or mood stabilising treatment for minimum 2 weeks
prior to inclusion in the study.
Exclusion criteria are any significant medical condi-
tions (incl. diabetes, renal failure, epilepsy, untreated
hypertension, present or past malignancies and throm-
bosis), smoking, hypertension, overweight (BMI > 30) or
a body weight < 45 or > 95 kg, schizophrenia, present
alcohol or substance misuse, acute suicidal risk, present
or previous suicide attempts in the past 2 years, preg-
nancy or breast feeding, contraceptive medication, or a
first-degree family history of thromboembolic events or
seizure disorders.
A pregnancy test will be performed on female patients
in their fertile age before and every second week during
the study. Blood screening and physical examinations
will be performed at baseline and every week during the
treatment period as well as 1, 2 and 6 weeks after treat-
ment cessation to monitor patients’ level of red blood
cells and ensure patient safety. Written informed con-
sent will be obtained from all patients before their inclu-
sion in the study and letters sent to their general
practitioners to avoid any potential medical
complications.
Randomisation
Block randomisation for the two studies has been per-
formed by Pharma Consulting Group AB http://www.
pharmaconsultinggroup.com. Pharma Consulting Group
has created randomisation lists for each study and emer-
gency envelopes for each patient ID number. Treatment
groups are stratified for age (< or ≥ 35 years) and gen-
der. Upon inclusion of participants, the date of birth,
gender, diagnosis, and to which of the above strata the
participant belongs are recorded. Numbering within
each stratum is consecutive and study identification
numbers are recorded in the patients’ individual case
report forms (CRFs).
Table 1 Overview of investigations
Interventions/
Assessment domains
Tests/Evaluations Screening Baseline &
treatment start
Active
treatment
phase
Treatment-free
follow-up period
Week 1 (Week 2-8) (Week 9-14)
Treatment Investigational drug EPO (40,000 IU)/Placebo - 1× 7× (weekly) -
Efficacy Neurocognitive functions Neuropsychological testing
(120 min)
- 1× - 2× (week 9,14)
MRI, fMRI and cognitive tests 1× - - 1× (week 14)
Psychopathology Clinical Rating - 1× 1× (week 5) 2× (week 9,14)
Questionnaires - 1× 1× (week 5) 2× (week 9,14)
Quality of life
questionnaires
- 1× 1× (week 5) 2× (week 9,14)
DXA scan - 1× - 1× (week 9)
Safety Physical exam 1× 1× 7× (weekly) 3× (week 9,10,14)
Vital signs 1× 1× 7× (weekly) 3× (week 9,10,14)
Urine pregnancy test 1× 1× 3× (week 3,5,7) -
ECG 1× - 2× (week 3,5) -
Adverse event
monitoring
- Continuously until week 10
Blood analysis Haematology 1× 1× 7× (weekly) 3× (week 9,10,14)
Blood chemistry 1× 1× 7× (weekly) 3× (week 9,10,14)
BDNF, inflammatory and
metabolic markers
- 1× 1× (week 5) 2× (week 9,14)
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Study personnel involved in the evaluation of outcomes
and Epo/placebo infusions and study participants are
blinded to study medication allocation. Blinding is main-
tained throughout the study, data management, outcome
assessment and data analysis. This is possible because
Epo is a clear colorless liquid similar to saline and
because safety monitoring and bloodlettings are per-
formed by a medic who is not involved in the evaluation
of outcome measures or drug administration.
Outcome assessments
The primary outcome for treatment-resistant depressed
patients (study 1) is depression severity as measured
with the HDRS-17 [1] at week 9. Global Assessment of
Function (GAF) scores at week 9 will be reported in
addition to the primary outcome. The secondary out-
come is remission defined as HDRS score ≤ 8 at week 9.
Confidence intervals will be reported in relation to the
proportions in remission. The tertiary outcomes are
memory and executive functions, measured with the Rey
Auditory Verbal Learning Test (RAVLT) [2,3] and Rapid
Visual Processing (RVIP) test from the Cambridge Neu-
ropsychological Test Automated Battery (CANTAB),
respectively, facial expression recognition measured with
a facial expression recognition test, as well as self-ratings
of cognitive difficulties on the CPFQ, depressive symp-
toms and life quality at week 9.
For bipolar patients in remission (study 2) the primary
outcome is memory performance measured with the
RAVLT at week 9. The secondary outcome is sustained
attention measured with the RVIP test and recognition
of emotional facial expressions assessed with a facial
expression recognition test at week 9. Finally, the ter-
tiary outcomes are ratings of mood, symptoms, quality
of life and cognitive function at week 9.
Clinical mood ratings and patients’ self-ratings will be
performed at baseline, and weeks 5, 9 and 14 to assess
the speed and duration of potential effects on these
measures. Neuropsychological testing is performed at
baseline, and weeks 9 and 14 to assess effects of Epo vs.
placebo treatment and their duration. For overview see
table 1.
Hypotheses
For study 1, it is hypothesised that Epo vs. placebo
treatment will: 1) reduce HDRS-17 scores 2) increase
remission rates measured with the HDRS-17 3) improve
memory and executive function, reduce the perception
of negative facial expressions, and improve symptoms
and quality of life.
Study 2 is designed to test the hypothesis that Epo vs.
placebo treatment will: 1) improve memory 2) facilitate
sustained attention and reduce the perception of
negative facial expressions measured, and 3) improve
mood, symptoms and life quality.
Further outcome assessments: biomarkers of potential
clinical effects
fMRI is performed before and after treatment to investi-
gate the neurophysiological underpinnings for effects of
repeated Epo administrationo nc o g n i t i v ef u n c t i o na n d
mood. The second fMRI scan is scheduled 6 weeks after
treatment cessation (week 14) because hematocrit levels
in the two groups should be comparable at this time
point [20] and thus not confound data interpretation.
We will investigate whether potential memory improve-
ment after Epo vs. placebo administration is associated
with increased hippocampal engagement during picture
encoding consistent with increased hippocampal BDNF
and plasticity [34,38]. The neural correlates of potential
improvements in executive function with Epo vs.
placebo treatment will be investigated with a spatial
N-back working memory test. Finally, we will investigate
whether potential antidepressant effects of Epo are
accompanied by reduced cognitive and neural response
to fearful facial expressions in a face-processing test
similar to effects seen with existing antidepressants [32].
This would point to the modulation of emotional bias
as a common mechanistically important effect of com-
pounds with diverse neurochemical signalling mechan-
isms. Structural T1-weighted MRI and diffusion
weighted imaging (DWI) at these time points will inves-
tigate whether Epo-treatment induces structural changes
in the hippocampus and influences functional brain con-
nectivity, respectively. Arterial spin labelling (ASL) will
investigate whether Epo introduces enduring changes in
global and regional cerebral blood flow (after the return
of haematocrit levels to baseline).
It is known that Epo increase hippocampal BDNF and
nerve growth factor (NGF) and has anti-inflammatory
actions, but it is unclear whether these actions are
mechanistically important for potential antidepressant
effects of Epo. We will therefore investigate the effect of
Epo on plasma and whole blood BDNF, NGF and
inflammatory markers incl. interleukin-6 (IL-6) and
C-reactive protein (CRP). Given diurnal variation in per-
ipheral BDNF, blood samples are collected at approxi-
mately the same time for all patients. For overview of
timing see table 1.
Preclinical research suggests that Epo protects against
diet-induced obesity and has beneficial effects on meta-
bolic parameters [45], which may play a role in the
treatment of affective disorder [46]. The study therefore
investigates the effects of Epo on metabolic parameters
(fasting glucose, fasting insulin, HgbA1c, HDL-
cholesterol, LDL-cholesterol and TAG) in these patients
through blood sampling before and during Epo vs.
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Medical Systems Wisconsin, USA, version 8.8) is per-
formed to assess whether Epo affects the total lipid- and
lipid-free lean mass in the body. For overview of timing
see table 1.
Sample size and power calculation
Sample size and statistical power for the two studies were
calculated using nQuery Advisor 5.0 software. The pri-
mary outcome in study 1 is depression severity reflected
by HDRS-17 after Epo vs. placebo treatment. The clini-
cally relevant difference is defined as minimum 3 scores
on this scale. The mean standard deviation in the two
treatment groups is estimated to be 3 HDRS-17 scores
and the mean scores to be 18 and 21 after Epo and pla-
cebo treatment, respectively. With these assumptions a
sample of n = 40 patients (n = 20 per drug group) has a
statistical power of 86% to detect a clinically relevant dif-
ference in HDRS-17 scores between the two treatment
groups at an alpha level of 5% (2-sided test).
The primary outcome in study 2 is verbal memory,
reflected by the RAVLT total score after Epo vs. placebo
treatment. A recent study has shown that the mean
RAVLT total score for patients with bipolar disorder in
remission is 52.0 (while the mean score for healthy age-
matched controls was 60.7) out of a maximum of 75
[47]. We estimate that a clinically relevant difference
between drug groups in the change in RAVLT scores is
at least 4 points (half-way to normal function). The
mean standard deviation in RAVLT scores in the two
treatment groups is estimated to be 4 points and the
mean scores to be 56 and 52 after Epo and placebo
treatment, respectively. With these assumptions a sam-
ple of n = 40 patients (n = 20 per drug group) has a sta-
tistical power of 86% to detect a clinically relevant
difference in RAVLT total scores between the two treat-
ment groups at an alpha level of 5% (2-sided test).
Psychological tests
The key aspects of cognitive function affected in mood
disorder, executive function, attention, memory and
emotional processing, are assessed using an extensive
battery of neurocognitive tests. The test battery includes
following manual tests: RAVLT, Verbal and Semantic
Fluency Tests, WAIS-III Letter Number Sequencing,
Trail Making A and B, the Repeatable Battery for the
Assessment of Neuropsychological Status (RBANS) digit
span and coding tests, and the following computerised
tests: Simple Reaction Time, Rapid Visual Information
Processing, Delayed Match to Sample and Spatial Work-
ing Memory. Tests used for fMRI scanning are an N-
back working memory task, a picture encoding task
modified from Hariri et al [38], an emotional face pro-
cessing task using fearful and happy Nimstim picture
stimuli http://www.macbrain.org/resources.htm and a
facial expression recognition task using Ekman and
Friesen morphed stimuli sets [48].
Equipment
The computerised neuropsychological test battery CAN-
TAB (Cambridge Cognition Ltd.) are employed for a
precise estimation of drug effects on accuracy and reac-
tion times during the above mentioned tasks probing
executive function, attention and memory. The effects
of Epo on the neural basis of executive function, mem-
ory and emotion processing as well as potential struc-
tural changes are investigated using the in vivo non-
invasive techniques of fMRI, structural T1 weighted
MRI, DWI, and ASL-based measurements of cerebral
blood flow. Imaging data will be collected using a Sie-
mens Trio scanner operating at 3.0 T, at the Danish
Research Centre for Magnetic Resonance (DRCMR),
Copenhagen University Hospital, Hvidovre. fMRI data
will pre-processed and analysed using FEAT (FMRIB
Expert Analysis Tool) version 5.43, part of FSL (FMRIB
Software Library version 3.3) http://www.fmrib.ox.ac.uk/
fsl. Structural T1-weighted MRI data is analysed with
FAST (FMRIB’s Automated Segmentation Tool), FIRST
(FMRIB’s Integrated Registration and Segmentation
Tool) http://www.fmrib.ox.ac.uk/fsl and FreeSurfer
http://surfer.nmr.mgh.harvard.edu/. DWI data is ana-
lysed with FDT (FMRIB’s Diffusion Toolbox; http://
www.fmrib.ox.ac.uk/fsl/fdt/). Finally analysis of ASL data
is performed with SPM software http://www.fil.ion.ucl.
ac.uk/spm/software/spm8/ and FABBER http://www.
fmrib.ox.ac.uk/fsl/fabber.
Statistical analyses
Data will be collected until dropout from all randomised
patients and analysed using repeated measures analysis
of variance (ANOVA). Significant interactions were ana-
lysed further with simple main effect analyses. In the
case of missing or invalid data, we will perform Per Pro-
tocol (PP) analyses for complete data sets and Intention
to Treat (ITT) analysis. In the case of disparity between
the results of these analyses, the outcome of the ITT
analysis will be regarded as the result of the study. The
statistical threshold for which results are considered sig-
nificant if p ≤ 0.05 (2-tailed). Statistical analyses will be
performed using the Statistical Package for Social
Sciences (SPSS).
Data management
Data for each participant is kept in a Case Record File
(CRF), which fulfil the Danish law for medical doctors’
obligation to keep patients records. The study personnel
involved in the evaluation of clinical outcomes are
blinded to the treatment until the data analysis is
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adverse effects are therefore kept separately in a locked
safe to which only medical doctors responsible for
patient safety and the person involved in the blinding of
the study medication have access.
Safety
Safety profile of Epo
Epo is widely used in the treatment of anaemia and gen-
erally has a good safety profile. Some potential acute side
effects are transient flu-like symptoms, rash at the injec-
tion site and headache, which are normally reported as
mild and disappear within a few hours. However, long-
term Epo-treatment can induce epileptic seizures in
medically ill patients with chronic renal failure and past
history of seizures [49]. A very rare adverse effect of Epo
treatment is a condition where the patient develops neu-
tralising antibodies against Epo resulting in pure red cell
aplasia (PRCA). This problem has only been observed in
patients treated with subcutaneous injections and was
solved in 2003 when the manufacturer changed the pre-
paration, packaging and transport of Epo [50]. Today,
Epo-antibody formation is thus an extremely rare condi-
tion observed with long-term subcutaneous Epo-
treatment of patients with chronic renal failure [51].
Meta-analysis of 5243 renal failure patients in long-
term Epo treatment showed a slight increase in
mortality (17%; 95% C.I. 1-35%) potentially because of
thrombosis at patients’ arterial dialysis access site and
insufficient treatment of hypertension [52]. Recently, a
study of 522 stroke patients treated with Epo vs. placebo
also revealed greater mortality in the Epo group, possi-
bly because of interaction with recombinant tissue plas-
minogen activator (rtPA) used for thrombolysis as well
as an unusual low death rate in the placebo group [53].
Weekly high-dose (40,000/48,000 IE) Epo administra-
tion to patients with neuropsychiatric disorder increases
haematocrit after 5 weeks [20,21] calling for bloodlettings
in about 40% of patients when values exceed 50% and
48% for men and women, respectively. However, contin-
ued Epo-treatment in the absence of any iron substitu-
tion was well tolerated and not associated with further
haematocrit increase after 8 weeks of treatment [20,21].
Safety precautions
Given the above safety concerns and increased mortality
in certain patient groups, the study inclusion and exclu-
sion criteria (see ‘Patients and screening’) are strictly
adhered to and patients’ safety monitored closely
throughout the study. Given the very low incidence of
PRCA, our use of intravenous (vs. subcutaneous) admin-
istration and exclusion of patients with renal failure, we
believe that the risk of PRCA in the current study is
negligible. Nevertheless, reticulocyte counts as first indi-
cator of PRCA will be carefully monitored (see below).
Patients are informed of all potential adverse effects
before their inclusion in the study, instructed that iron
supplements are strictly prohibited (since they would
boost haematocrit levels) and advised to immediately
contact their local emergency department if (1) they
experience any potential symptoms of thrombosis or (2)
their physician suspects PRCA. They are given a pocket-
size plastic card with instruction about whom to contact
in the event of these symptoms, their contact details,
and important information to the medical doctor at the
local emergency department.
It is ensured the temperature of the Epo is kept at 2-
8°C at all times during transport and storage to avoid
damage of the compound and potential associated
adverse effects. To minimise the risk of acute allergic
reactions, Epo/placebo is dissolved in 100 ml saline and
administered as intravenous infusions over 15 minutes.
After this, patients’ well-being is monitored for at least
30 minutes by a nurse at the clinic in the case of poten-
tial transient side effects of Epo like flu symptoms, rash
at the infusion site or head ache.
Safety parameters and monitoring
Patient safety is monitored with medical examinations,
blood pressure measurements, blood tests, ECG and
other safety measures at baseline and throughout the
study until 2 weeks after cessation of Epo/placebo treat-
ment. For an overview of the safety tests, their frequency
and timing see table 1.
If blood tests show significantly increased haematocrit
(>50% for men and >48% for women) at two consecu-
tive measurements within a week, bloodletting(s) (450
ml each) will be performed weakly with no cessation of
treatment until haematocrit values are normalised. In
the case of significant increase in thrombocytes (> 400
billion/L) or drop in reticulocytes (< 1‰) 2 repeated
controls will be performed in the following week. If
these values remain abnormal, the patient is taken out
of the study and monitored with weekly medical exami-
nations and blood tests until the values are normalised
or is hospitalised for observation.
Procedures for acting on serious adverse effects
Procedures for breaking the randomisation code are
established for the case of severe adverse reactions
potentially related to the drug intervention. These will
be followed when knowledge of the patient’s drug treat-
ment will have implications of the treatment of the
observed adverse effects. It is the decision of the princi-
pal investigator or the medic responsible for safety mon-
itoring to break the emergency envelope for the affected
participant.
Discussion
The present EPO study is the first clinical trial investi-
gating whether repeated administration of Epo is able to
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in patients with treatment resistant depression or bipo-
lar illness in remission. In light of the hypothesis that
neural plasticity and neurogenesis play a prominent role
in the pathophysiology of affective disorders, cognitive
function and clinical response to drug treatment, Epo is
a compound worth to be considered for future add-on
treatment strategies. It is hypothesised that Epo treat-
ment will have antidepressant effects in patients with
treatment resistant depression and alleviate the enduring
neurocognitive dysfunction in patients with bipolar dis-
order in remission.
Current trial status
Patient enrolment started in September 2009 and is
ongoing until September 2013. Status in October 2010
is that 21 participants have been screened, enrolled and
randomised. One patient has had to drop out after week
5 because of abnormal laboratory results. So far, data
sets including all clinical variables and biomarkers are
complete for 18 participants.
Ethical considerations
Better treatment options are required to improve the
onset of efficacy, address the significant proportion of
patients who are treatment resistant and reverse neuro-
cognitive deficits in patients with affective disorders.
Compounds, which induce rapid and prolonged upregu-
lation of neuroplasticity may reduce the latency to anti-
depressant effects and alleviate neurocognitive
dysfunction. Epo has such neuroregenerative properties,
which make it a candidate for investigation as a novel
therapeutic agent. We have recently demonstrated a
beneficial effect of Epo on neurocognitive function and
mood in healthy volunteers and antidepressant-like
effects in acutely depressed patients. However, it is
unclear whether repeated Epo treatment has antidepres-
sant effects and improves neurocognitive function in
patients with affective disorders. The present study will
thus increase our knowledge about the role of neuro-
plasticity in affective disorders and perhaps contribute
to development of new, better treatment strategies.
Participants in the present study are patients with
treatment-resistant depression (study 1) and patients
with bipolar disorder in full or partial remission who
suffer from persistent cognitive difficulties (study 2). For
both patient groups there are a number of benefits
related to taking part in the study. For treatment-
resistant depression, defined as lack of effect of medica-
tion from minimum 2 different classes of antidepres-
sants given in sufficient doses over sufficient time
[54,55], there is no scientific evidence for effect of addi-
tional pharmacological treatment. Further, cognitive
function remains impaired in many patients with bipolar
disorder even after clinical remission. If the study reveals
positive effects of Epo on mood and cognitive function,
this would highlight Epo as a new potential treatment for
these patient groups in the future. All patients have close
contact to a medical doctor, a research nurse and a psy-
chologist for the duration of the study, which has shown
beneficial effects in previous studies [56]. Finally, patients
are remunerated for their time and transport expenses
related to taking part in the study.
There are also some risks and inconveniences for
patients in the study. Although they will maintain their
current antidepressant or mood stabilising treatment,
they are requested to not make any changes in their
medication for the duration of the study. This may give
rise to ethical considerations for the acutely depressed
patients in study 1. Nevertheless, these patients are
characterised by treatment-resistance to currently avail-
able antidepressant medication and it is unclear which
treatment would help this group. Therefore, keeping
patients’ treatment constant for the duration of the Epo/
placebo treatment does not impose any significant ethi-
cal dilemmas. Finally, there are some health risks asso-
ciated with Epo treatment as previously described.
However, we consider these to be negligible in light of
safety data from previous Epo studies and the described
exclusion criteria, safety precautions and close safety
monitoring performed throughout the study.
Given the above ethical considerations, we believe that
participants’ risks and inconveniences are minimal and
outweighed by their benefits and by the potential impli-
cations of the trial for future management of mood
symptoms and cognitive functioning in these patient
groups.
Limitations
A major limitation of the study design is the implemen-
tation of many exclusion criteria (see ‘Patients and
screening’), which serves to maximise participant safety.
This limits the generalizability of the findings to clinical
practice. Specifically, our sample may not be particularly
representative for the full range of physical and psychia-
tric comorbidity, response to treatment and functioning
of patients seen in the clinic. Nevertheless, this limita-
tion is considered inevitable since patient safety is of
principal importance.
From a clinical perspectivet h e r ea r et w op o t e n t i a l
complications of long-term application of Epo to
patients with affective disorders. The first problem is the
increases in the red cell mass observed with repeated
administration leading to increased risk of hypertension
and blood clotting [57]. Future studies may wish to
assess whether such unwanted haematopoietic activities
can be avoided with infrequent Epo administration
while maintaining the neuroprotective effects. Another
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such as carbamylated Epo (CEPO) and asialoerythro-
poietin (asialoEPO) which have been engineered to have
neuroprotective but not haematopoietic actions [58-60].
In the absence of haematological activities, CEPO and
asialoEPO exhibit a broad spectrum of neuroprotective
activities in models of cerebral ischemia, spinal cord
injury and sciatic nerve crush [58,61-63]. These Epo
derivatives may thus be promising candidates for long-
term treatment of affective disorders.
The second major limitation of Epo as a clinical
treatment of affective disorders is the availability of
only intravenous or subcutaneous administration
routes, which by many is experienced as unpleasant
and increases the costs of EPO treatment. However,
alternative administration routes with easier applica-
tion and lower costs are currently being explored. In
particular, intranasal administration of small doses of
Epo has recently been found to penetrate the BBB and
attenuate acute cerebral ischemic injuries in rats [64].
This suggests that intranasal administration of Epo
could become a simple and non-invasive method to
treat acute brain trauma and neuropsychiatric condi-
tions in the future. Another clinical benefit of intrana-
sal application is the necessity of significantly smaller
doses of Epo for neuroprotection, which may reduce
the potentially systemic side effects resulting from ery-
thropoietic activity [64]. Assessment of the safety of
intranasal Epo administration in man is thus an
important next step before assessment of the neuro-
cognitive effects of Epo with this route of administra-
tion in man.
Perspectives
If the present trial reveals beneficial effects of Epo on
mood and neurocognitive function in patients with
treatment resistant depression and patients with
remitted bipolar disorder, this would highlight Epo and
its non-haematopoietic derivatives as candidate com-
pounds for future ‘cognitive enhancement’ treatment
strategies for affective disorders. This could have signifi-
cant implications for patient health and economical bur-
den for the society in the future.
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